Arrowsmith

About Arrowsmith

Arrowsmith Inc. is a biopharmaceutical startup established on February 3, 2025, by CEO and CScO Hiroki Ando. The company focuses on developing novel treatments for bacterial infections, particularly those resistant to conventional antibiotics, through an approach known as phage therapy. This therapy utilizes bacteriophages, which are viruses that specifically target and infect bacteria, to offer a new therapeutic option against the growing global health threat of antimicrobial resistance (AMR).

The company's foundation is built upon five years of collaborative research (starting in 2020) between Astellas Pharma Inc. and Gifu University. Arrowsmith's lead pipeline candidate is ARW001, a phage cocktail designed to treat infections caused by Pseudomonas aeruginosa, a common source of hospital-acquired and medical device-related infections. ARW001 is a multi-phage composition that features broad applicability, high bactericidal efficacy, and stability. It incorporates genetically modified phages created using Arrowsmith's proprietary synthesis and modification techniques, which enables the breakdown of biofilms—protective barriers formed by bacteria that complicate treatment.

Shortly after its inception, Arrowsmith secured significant funding in August 2025. This included a JPY 300 million pre-Series A round from investors JAFCO Group Co., Ltd., and JIC Venture Growth Investments Co., Ltd. Concurrently, the company's lead program, ARW001, was selected for the "Strengthening Program for the Pharmaceutical Startup Ecosystem" by the Japan Agency for Medical Research and Development (AMED), securing an initial JPY 460 million and access to a framework of up to JPY 5 billion. This capital is intended to accelerate the research and development of ARW001 through non-clinical and clinical trials and to advance subsequent product pipelines.